Vis enkel innførsel

dc.contributor.authorDunwell, Thomas L.
dc.contributor.authorDailey, Simon C.
dc.contributor.authorOttestad, Anine Larsen
dc.contributor.authorYu, Jihang
dc.contributor.authorBecker, Philipp W.
dc.contributor.authorScaife, Sarah
dc.contributor.authorRichman, Susan D.
dc.contributor.authorWood, Henry M.
dc.contributor.authorSlaney, Hayley
dc.contributor.authorBottomley, Daniel
dc.contributor.authorYang, Xiangsheng
dc.contributor.authorXiao, Hui
dc.contributor.authorWahl, Sissel Gyrid Freim
dc.contributor.authorGrønberg, Bjørn Henning
dc.contributor.authorDai, Hong Yan
dc.contributor.authorFu, Guoliang
dc.date.accessioned2021-03-01T09:03:45Z
dc.date.available2021-03-01T09:03:45Z
dc.date.created2021-02-11T09:46:19Z
dc.date.issued2021
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/11250/2730811
dc.description.abstractLiquid biopsy testing utilising Next Generation Sequencing (NGS) is rapidly moving towards clinical adoption for personalised oncology. However, before NGS can fulfil its potential any novel testing approach must identify ways of reducing errors, allowing separation of true low-frequency mutations from procedural artefacts, and be designed to improve upon current technologies. Popular NGS technologies typically utilise two DNA capture approaches; PCR and ligation, which have known limitations and seem to have reached a development plateau with only small, stepwise improvements being made. To maximise the ultimate utility of liquid biopsy testing we have developed a highly versatile approach to NGS: Adaptor Template Oligo Mediated Sequencing (ATOM-Seq). ATOM-Seq's strengths and versatility avoid the major limitations of both PCR- and ligation-based approaches. This technology is ligation free, simple, efficient, flexible, and streamlined, and it offers novel advantages that make it perfectly suited for use on highly challenging clinical material. Using reference and clinical materials, we demonstrate detection of known SNVs down to allele frequencies of 0.1% using as little as 20–25 ng of cfDNA, as well as the ability to detect fusions from RNA. We illustrate ATOM-Seq’s suitability for clinical testing by showing high concordance rates between paired cfDNA and FFPE clinical samples.en_US
dc.language.isoengen_US
dc.publisherNature Researchen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleAdaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-sensitive UMI-based NGS library preparation technology for use with cfDNA and cfRNAen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.journalScientific Reportsen_US
dc.identifier.doi10.1038/s41598-021-82737-9
dc.identifier.cristin1888743
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal